Wall Street Sees Woodcock Commissionership As Positive for Aducanumab, But Eyes Should Be On Cavazzoni

 
• By Sarah Karlin-Smith

Review extension for Alzheimer’s candidate may be positive for Biogen, but it’s not because Woodcock is acting commissioner. To understand the odds, it may be time to get to better know a new generation of US FDA’s drug review leadership.

Acting CDER Director Patrizia Cavazzoni may have to think more about aducanumab, but Acting US FDA Commissioner Janet Woodcock is front of mind for Wall Street analysts. • Source: photo illustration

More from Agency Leadership

More from Pink Sheet